{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:20:53Z","timestamp":1790738453540,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Front. Med."],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s11684-019-0689-5","type":"journal-article","created":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T07:41:31Z","timestamp":1551339691000},"page":"398-408","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Urotensin II receptor antagonist reduces hepatic resistance and portal pressure through enhanced eNOS-dependent HSC vasodilatation in CCl4-induced cirrhotic rats"],"prefix":"10.1007","volume":"13","author":[{"given":"Ruoxi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diangang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,11]]},"reference":[{"issue":"4","key":"689_CR1","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.1097\/01.mcg.0000155552.14396.3d","volume":"6","author":"RJ Groszmann","year":"2005","unstructured":"Groszmann RJ, Abraldes JG. Portal hypertension: from bedside to bench. J Clin Gastroenterol 2005; 6(4 Suppl 2): S125\u2013S130","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"689_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s12072-017-9826-x","volume":"12","author":"M McConnell","year":"2018","unstructured":"McConnell M, Iwakiri Y. Biology of portal hypertension. Hepatol Int 2018; 12(Suppl 1):11\u201323","journal-title":"Hepatol Int"},{"issue":"6","key":"689_CR3","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1002\/hep.29084","volume":"65","author":"M Vilaseca","year":"2017","unstructured":"Vilaseca M, Garc\u00eda-Calder\u00f3 H, Lafoz E, Garc\u00eda-Irigoyen O, Avila MA, Reverter JC, Bosch J, Hern\u00e1ndez-Gea V, Gracia-Sancho J, Garc\u00eda-Pag\u00e1n JC. The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells. Hepatology 2017; 65(6): 2031\u20132044","journal-title":"Hepatology"},{"issue":"7","key":"689_CR4","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1111\/liv.13436","volume":"37","author":"M Vilaseca","year":"2017","unstructured":"Vilaseca M, Garc\u00eda-Calder\u00f3 H, Lafoz E, Ruart M, L\u00f3pez-Sanjurjo CI, Murphy MP, Deulofeu R, Bosch J, Hern\u00e1ndez-Gea V, Gracia-Sancho J, Garc\u00eda-Pag\u00e1n JC. Mitochondria-targeted antioxidant mitoquinone deactivates human and rat hepatic stellate cells and reduces portal hypertension in cirrhotic rats. Liver Int 2017; 37(7): 1002\u20131012","journal-title":"Liver Int"},{"issue":"2","key":"689_CR5","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/hep.510270222","volume":"27","author":"DC Rockey","year":"1998","unstructured":"Rockey DC, Fouassier L, Chung JJ, Carayon A, Vallee P, Rey C, Housset C. Cellular localization of endothelin-1 and increased production in liver injury in the rat: potential for autocrine and paracrine effects on stellate cells. Hepatology 1998; 27(2): 472\u2013480","journal-title":"Hepatology"},{"issue":"2","key":"689_CR6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cld.2013.12.001","volume":"18","author":"Y Iwakiri","year":"2014","unstructured":"Iwakiri Y. Pathophysiology of portal hypertension. Clin Liver Dis 2014; 18(2): 281\u2013291","journal-title":"Clin Liver Dis"},{"issue":"1","key":"689_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0006-8993(00)02377-5","volume":"871","author":"Y Nishimura","year":"2000","unstructured":"Nishimura Y, Ito T, Hoe K, Saavedra JM. Chronic peripheral administration of the angiotensin II AT(1) receptor antagonist candesartan blocks brain AT(1) receptors. Brain Res 2000; 871(1): 29\u201338","journal-title":"Brain Res"},{"issue":"6750","key":"689_CR8","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/45809","volume":"401","author":"RS Ames","year":"1999","unstructured":"Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, Louden CS, Foley JJ, Sauermelch CF, Coatney RW, Ao Z, Disa J, Holmes SD, Stadel JM, Martin JD, Liu WS, Glover GI, Wilson S, McNulty DE, Ellis CE, Elshourbagy NA, Shabon U, Trill JJ, Hay DW, Ohlstein EH, Bergsma DJ, Douglas SA. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999; 401(6750): 282\u2013286","journal-title":"Nature"},{"issue":"5","key":"689_CR9","doi-asserted-by":"publisher","first-page":"R1156","DOI":"10.1152\/ajpregu.00706.2009","volume":"298","author":"B Ross","year":"2010","unstructured":"Ross B, McKendy K, Giaid A. Role of urotensin II in health and disease. Am J Physiol Regul Integr Comp Physiol 2010; 298(5): R1156\u2013R1172","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"10","key":"689_CR10","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/j.peptides.2004.05.027","volume":"25","author":"G Thanassoulis","year":"2004","unstructured":"Thanassoulis G, Huyhn T, Giaid A. Urotensin II and cardiovascular diseases. Peptides 2004; 25(10): 1789\u20131794","journal-title":"Peptides"},{"issue":"5","key":"689_CR11","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.peptides.2007.08.020","volume":"29","author":"W Kemp","year":"2008","unstructured":"Kemp W, Roberts S, Krum H. Increased circulating urotensin II in cirrhosis: potential implications in liver disease. Peptides 2008; 29 (5): 868\u2013872","journal-title":"Peptides"},{"issue":"6","key":"689_CR12","first-page":"845","volume":"25","author":"D Liu","year":"2010","unstructured":"Liu D, Chen J, Wang J, Zhang Z, Ma X, Jia J, Wang Y. Increased expression of urotensin II and GPR14 in patients with cirrhosis and portal hypertension. Int J Mol Med 2010; 25(6): 845\u2013851","journal-title":"Int J Mol Med"},{"issue":"6","key":"689_CR13","first-page":"953","volume":"2","author":"DG Liu","year":"2009","unstructured":"Liu DG, Wang J, Zhang ZT, Wang Y. The urotension II antagonist SB-710411 arrests fibrosis in CCl4 cirrhotic rats. Mol Med Rep 2009; 2(6): 953\u2013961","journal-title":"Mol Med Rep"},{"issue":"1","key":"689_CR14","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1124\/jpet.104.068320","volume":"311","author":"M Clozel","year":"2004","unstructured":"Clozel M, Binkert C, Birker-Robaczewska M, Boukhadra C, Ding SS, Fischli W, Hess P, Mathys B, Morrison K, M\u00fcller C, M\u00fcller C, Nayler O, Qiu C, Rey M, Scherz MW, Velker J, Weller T, Xi JF, Ziltener P. Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)- ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin system. J Pharmacol Exp Ther 2004; 311(1): 204\u2013212","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"689_CR15","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1136\/gutjnl-2014-307138","volume":"64","author":"M Mejias","year":"2015","unstructured":"Mejias M, Coch L, Berzigotti A, Garcia-Pras E, Gallego J, Bosch J, Fernandez M. Antiangiogenic and antifibrogenic activity of pigment epithelium-derived factor (PEDF) in bile duct-ligated portal hypertensive rats. Gut. 2015; 64(4): 657\u2013666","journal-title":"Gut."},{"issue":"3","key":"689_CR16","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1124\/jpet.105.094821","volume":"316","author":"M Clozel","year":"2006","unstructured":"Clozel M, Hess P, Qiu C, Ding SS, Rey M. The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats. J Pharmacol Exp Ther 2006; 316(3): 1115\u20131121","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"689_CR17","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1002\/hep.27679","volume":"61","author":"SJ Hsu","year":"2015","unstructured":"Hsu SJ, Lee FY, Wang SS, Hsin IF, Lin TY, Huang HC, Chang CC, Chuang CL, Ho HL, Lin HC, Lee SD. Caffeine ameliorates hemodynamic derangements and portosystemic collaterals in cirrhotic rats. Hepatology 2015; 61(5): 1672\u20131684","journal-title":"Hepatology"},{"issue":"7","key":"689_CR18","doi-asserted-by":"publisher","first-page":"G496","DOI":"10.1152\/ajpgi.00336.2012","volume":"305","author":"MG Delgado","year":"2013","unstructured":"Delgado MG, Gracia-Sancho J, Marrone G, Rodr\u00edguez-Vilarrupla A, Deulofeu R, Abraldes JG, Bosch J, Garc\u00eda-Pag\u00e1n JC. Leptin receptor blockade reduces intrahepatic vascular resistance and portal pressure in an experimental model of rat liver cirrhosis. Am J Physiol Gastrointest Liver Physiol 2013; 305(7): G496\u2013G502","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"4","key":"689_CR19","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2340\/16501977-0313","volume":"41","author":"AS Darlington","year":"2009","unstructured":"Darlington AS, Dippel DW, Ribbers GM, van Balen R, Passchier J, Busschbach JJ. A prospective study on coping strategies and quality of life in patients after stroke, assessing prognostic relationships and estimates of cost-effectiveness. J Rehabil Med 2009; 41(4): 237\u2013241","journal-title":"J Rehabil Med"},{"issue":"17","key":"689_CR20","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1161\/01.CIR.103.17.2188","volume":"103","author":"A M\u00fclsch","year":"2001","unstructured":"M\u00fclsch A, Oelze M, Kl\u00f6ss S, Mollnau H, T\u00f6pfer A, Smolenski A, Walter U, Stasch JP, Warnholtz A, Hink U, Meinertz T, M\u00fcnzel T. Effects of in vivo nitroglycerin treatment on activity and expression of the guanylyl cyclase and cGMP-dependent protein kinase and their downstream target vasodilator-stimulated phosphoprotein in aorta. Circulation 2001; 103(17): 2188\u20132194","journal-title":"Circulation"},{"issue":"6","key":"689_CR21","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/nprot.2008.73","volume":"3","author":"TD Schmittgen","year":"2008","unstructured":"Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008; 3(6): 1101\u20131108","journal-title":"Nat Protoc"},{"issue":"8","key":"689_CR22","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/j.1440-1746.1998.tb00747.x","volume":"13","author":"GA Ramm","year":"1998","unstructured":"Ramm GA. Isolation and culture of rat hepatic stellate cells. J Gastroenterol Hepatol 1998; 13(8): 846\u2013851","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"689_CR23","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/hep.510240137","volume":"24","author":"DC Rockey","year":"1996","unstructured":"Rockey DC, Weisiger RA. Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance. Hepatology 1996; 24 (1): 233\u2013240","journal-title":"Hepatology"},{"issue":"2","key":"689_CR24","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/00029330-200801020-00013","volume":"121","author":"J Liu","year":"2008","unstructured":"Liu J, Gong H, Zhang ZT, Wang Y. Effect of angiotensin II and angiotensin II type 1 receptor antagonist on the proliferation, contraction and collagen synthesis in rat hepatic stellate cells. Chin Med J (Engl) 2008; 121(2): 161\u2013165","journal-title":"Chin Med J (Engl)"},{"issue":"9","key":"689_CR25","first-page":"1232","volume":"27","author":"W Kemp","year":"2007","unstructured":"Kemp W, Krum H, Colman J, Bailey M, Yandle T, Richards M, Roberts S. Urotensin II: a novel vasoactive mediator linked to chronic liver disease and portal hypertension. Liver Int 2007; 27(9): 1232\u20131239","journal-title":"Liver Int"},{"issue":"4","key":"689_CR26","doi-asserted-by":"publisher","first-page":"G762","DOI":"10.1152\/ajpgi.00127.2009","volume":"297","author":"W Kemp","year":"2009","unstructured":"Kemp W, Kompa A, Phrommintikul A, Herath C, Zhiyuan J, Angus P, McLean C, Roberts S, Krum H. Urotensin II modulates hepatic fibrosis and portal hemodynamic alterations in rats. Am J Physiol Gastrointest Liver Physiol 2009; 297(4): G762\u2013G767","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"4","key":"689_CR27","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/j.1365-2125.2009.03480.x","volume":"68","author":"PN Sidharta","year":"2009","unstructured":"Sidharta PN, Rave K, Heinemann L, Chiossi E, Kr\u00e4henb\u00fchl S, Dingemanse J. Effect of the urotensin-II receptor antagonist palosuran on secretion of and sensitivity to insulin in patients with type 2 diabetes mellitus. Br J Clin Pharmacol 2009; 68(4): 502\u2013510","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"689_CR28","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1002\/hep.22170","volume":"47","author":"J Trebicka","year":"2008","unstructured":"Trebicka J, Leifeld L, Hennenberg M, Biecker E, Eckhardt A, Fischer N, Pr\u00f6bsting AS, Clemens C, Lammert F, Sauerbruch T, Heller J. Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats. Hepatology 2008; 47 (4): 1264\u20131276","journal-title":"Hepatology"},{"issue":"6","key":"689_CR29","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0168-8278(02)00295-7","volume":"37","author":"J Heller","year":"2002","unstructured":"Heller J, Schepke M, Neef M, Woitas R, Rabe C, Sauerbruch T. Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension. J Hepatol 2002; 37(6): 767\u2013772","journal-title":"J Hepatol"},{"issue":"5","key":"689_CR30","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1007\/s10620-009-0875-4","volume":"55","author":"L Leifeld","year":"2010","unstructured":"Leifeld L, Clemens C, Heller J, Trebicka J, Sauerbruch T, Spengler U. Expression of urotensin II and its receptor in human liver cirrhosis and fulminant hepatic failure. Dig Dis Sci 2010; 55(5): 1458\u20131464","journal-title":"Dig Dis Sci"},{"issue":"3","key":"689_CR31","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.7314\/APJCP.2014.15.3.1085","volume":"15","author":"L Yadav","year":"2014","unstructured":"Yadav L, Puri N, Rastogi V, Satpute P, Ahmad R, Kaur G. Matrix metalloproteinases and cancer-roles in threat and therapy. Asian Pac J Cancer Prev 2014; 15(3): 1085\u20131091","journal-title":"Asian Pac J Cancer Prev"},{"issue":"3","key":"689_CR32","doi-asserted-by":"publisher","first-page":"e0121383","DOI":"10.1371\/journal.pone.0121383","volume":"10","author":"LM Liu","year":"2015","unstructured":"Liu LM, Liang DY, Ye CG, Tu WJ, Zhu T. The UII\/UT system mediates upregulation of proinflammatory cytokines through p38 MAPK and NF-kB pathways in LPS-stimulated Kupffer cells. PLoS One 2015; 10(3): e0121383","journal-title":"PLoS One"},{"issue":"2","key":"689_CR33","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1053\/jhep.2002.31432","volume":"35","author":"R Wiest","year":"2002","unstructured":"Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 2002; 35(2): 478\u2013491","journal-title":"Hepatology"},{"issue":"6","key":"689_CR34","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1002\/hep.26939","volume":"59","author":"L Verbeke","year":"2014","unstructured":"Verbeke L, Farre R, Trebicka J, Komuta M, Roskams T, Klein S, Elst IV, Windmolders P, Vanuytsel T, Nevens F, Laleman W. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology 2014; 59(6): 2286\u20132298","journal-title":"Hepatology"},{"issue":"10","key":"689_CR35","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1136\/gutjnl-2016-312108","volume":"65","author":"A Mallat","year":"2016","unstructured":"Mallat A, Lotersztajn S. Targeting cannabinoid receptors in hepatocellular carcinoma. Gut 2016; 65(10):1582\u20131583","journal-title":"Gut"},{"issue":"3","key":"689_CR36","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1021\/mp9000469","volume":"6","author":"K Cheng","year":"2009","unstructured":"Cheng K, Yang N, Mahato RI. TGF-\u00df1 gene silencing for treating liver fibrosis. Mol Pharm 2009; 6(3): 772\u2013779","journal-title":"Mol Pharm"},{"issue":"10","key":"689_CR37","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s00204-015-1525-6","volume":"89","author":"RJ Chen","year":"2015","unstructured":"Chen RJ, Wu HH, Wang YJ. Strategies to prevent and reverse liver fibrosis in humans and laboratory animals. Arch Toxicol 2015; 89 (10): 1727\u20131750","journal-title":"Arch Toxicol"},{"issue":"1","key":"689_CR38","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/hep.21673","volume":"46","author":"J Trebicka","year":"2007","unstructured":"Trebicka J, Hennenberg M, Laleman W, Shelest N, Biecker E, Schepke M, Nevens F, Sauerbruch T, Heller J. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA\/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 2007; 46(1): 242\u2013253","journal-title":"Hepatology"}],"container-title":["Frontiers of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11684-019-0689-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11684-019-0689-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11684-019-0689-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T19:19:10Z","timestamp":1591730350000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11684-019-0689-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["689"],"URL":"https:\/\/doi.org\/10.1007\/s11684-019-0689-5","relation":{},"ISSN":["2095-0217","2095-0225"],"issn-type":[{"value":"2095-0217","type":"print"},{"value":"2095-0225","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"8 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}